Business
Vertex Pharmaceuticals Announces Webcasts of its Presentations at Three Investor Conferences
Vertex Pharmaceuticals Announces Webcasts of its Presentations at Three Investor Conferences.
About this update from Vortex Energy Corp.
[{"type":"text","content":"\n\n\n\n\nCAMBRIDGE, Mass., June 9 /CNW/ -- Vertex Pharmaceuticals\nIncorporated (Nasdaq: VRTX) today announced that it will webcast its\npresentations at three investor conferences:\n\n Pacific Growth Equities Life Sciences Growth Conference on Tuesday, June\n 13, 2006 at 10:30 a.m. PDT (1:30 p.m. EDT), presented by Ian Smith,\n Executive Vice President and Chief Financial Officer of Vertex\n\n Goldman Sachs 27th Annual Global Healthcare Conference on Wednesday,\n June 14, 2006 at 3:00 p.m. PDT (6:00 p.m. EDT), presented by Joshua\n Boger, Ph.D., President and Chief Executive Officer of Vertex\n\n Needham & Co. Fifth Annual Biotechnology and Medical Technology\n Conference on Thursday, June 15, 2006 at 8:30 a.m. EDT, presented by\n Lynne Brum, Vice President, Strategic Communications of Vertex\n\nEach presentation will be webcast live and may be accessed by visiting the\nVertex website at http://www.vrtx.com. A replay of the webcasts will also be\navailable on the Company's website for two weeks following the presentations.\nTo access the webcasts, go to Vertex's website and select the desired\npresentation from the 'Events Calendar.' To ensure a timely connection, it is\nrecommended that users register at least 15 minutes prior to the scheduled\nwebcast.\n\nAbout Vertex\nVertex Pharmaceuticals Incorporated is a global biotechnology company\ncommitted to the discovery and development of breakthrough small molecule\ndrugs for serious diseases. The Company's strategy is to commercialize its\nproducts both independently and in collaboration with major pharmaceutical\ncompanies. Vertex's product pipeline is principally focused on viral\ndiseases, inflammation, autoimmune diseases and cancer. In collaboration with\nGlaxoSmithKline, Vertex co-promotes the HIV protease inhibitor, Lexiva.\nLexiva is a registered trademark of the GlaxoSmithKline group of\ncompanies.\nVertex's press releases are available at http://www.vrtx.com.\n\nVertex Contact:\nLora Pike, Manager, Investor Relations, (617) 444-6755\n\n\n\n","length":2094,"tagName":"div"}]